These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 10854950)

  • 1. Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue.
    Tahir SK; Gu WZ; Zhang HC; Leal J; Lee JY; Kovar P; Saeed B; Cherian SP; Devine E; Cohen J; Warner R; Wang YC; Stout D; Arendsen DL; Rosenberg S; Ng SC
    Eur J Cancer; 2000 Jun; 36(9):1161-70. PubMed ID: 10854950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. J-104,871, a novel farnesyltransferase inhibitor, blocks Ras farnesylation in vivo in a farnesyl pyrophosphate-competitive manner.
    Yonemoto M; Satoh T; Arakawa H; Suzuki-Takahashi I; Monden Y; Kodera T; Tanaka K; Aoyama T; Iwasawa Y; Kamei T; Nishimura S; Tomimoto K
    Mol Pharmacol; 1998 Jul; 54(1):1-7. PubMed ID: 9658183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo.
    Gu WZ; Tahir SK; Wang YC; Zhang HC; Cherian SP; O'Connor S; Leal JA; Rosenberg SH; Ng SC
    Eur J Cancer; 1999 Sep; 35(9):1394-401. PubMed ID: 10658533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
    Rak J; Mitsuhashi Y; Bayko L; Filmus J; Shirasawa S; Sasazuki T; Kerbel RS
    Cancer Res; 1995 Oct; 55(20):4575-80. PubMed ID: 7553632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of human smooth muscle cell proliferation in culture by farnesyl pyrophosphate analogues, inhibitors of in vitro protein: farnesyl transferase.
    Cohen LH; Pieterman E; van Leeuwen RE; Du J; Negre-Aminou P; Valentijn AR; Overhand M; van der Marel GA; van Boom JH
    Biochem Pharmacol; 1999 Feb; 57(4):365-73. PubMed ID: 9933024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different analogues of farnesyl pyrophosphate inhibit squalene synthase and protein:farnesyltransferase to different extents.
    Cohen LH; Valentijn AR; Roodenburg L; Van Leeuwen RE; Huisman RH; Lutz RJ; Van der Marel GA; Van Boom JH
    Biochem Pharmacol; 1995 Mar; 49(6):839-45. PubMed ID: 7702642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein farnesyltransferase: measurement of enzymatic activity in 96-well format using TopCount microplate scintillation counting technology.
    Harwood HJ
    Anal Biochem; 1995 Apr; 226(2):268-78. PubMed ID: 7793628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new class of highly potent farnesyl diphosphate-competitive inhibitors of farnesyltransferase.
    Aoyama T; Satoh T; Yonemoto M; Shibata J; Nonoshita K; Arai S; Kawakami K; Iwasawa Y; Sano H; Tanaka K; Monden Y; Kodera T; Arakawa H; Suzuki-Takahashi I; Kamei T; Tomimoto K
    J Med Chem; 1998 Jan; 41(2):143-7. PubMed ID: 9457237
    [No Abstract]   [Full Text] [Related]  

  • 10. Arglabin-DMA, a plant derived sesquiterpene, inhibits farnesyltransferase.
    Shaikenov TE; Adekenov SM; Williams RM; Prashad N; Baker FL; Madden TL; Newman R
    Oncol Rep; 2001; 8(1):173-9. PubMed ID: 11115593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the novel farnesyltransferase inhibitor RPR130401 and the geranylgeranyltransferase-1 inhibitor GGTI-298 disrupts MAP kinase activation and G(1)-S transition in Ki-Ras-overexpressing transformed adrenocortical cells.
    Mazet JL; Padieu M; Osman H; Maume G; Mailliet P; Dereu N; Hamilton AD; Lavelle F; Sebti SM; Maume BF
    FEBS Lett; 1999 Oct; 460(2):235-40. PubMed ID: 10544242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
    Feldkamp MM; Lau N; Guha A
    Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Didehydrofarnesyl diphosphate: an intrinsically fluorescent inhibitor of protein farnesyltransferase.
    Liu XH; Prestwich GD
    Bioorg Med Chem Lett; 2004 May; 14(9):2137-40. PubMed ID: 15080995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TAN-1813, a novel Ras-farnesyltransferase inhibitor produced by Phoma sp. taxonomy, fermentation, isolation and biological activities in vitro and in vivo.
    Ishii T; Hayashi K; Hida T; Yamamoto Y; Nozaki Y
    J Antibiot (Tokyo); 2000 Aug; 53(8):765-78. PubMed ID: 11079798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
    Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
    Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor.
    Charvat S; Duchesne M; Parvaz P; Chignol MC; Schmitt D; Serres M
    Anticancer Res; 1999; 19(1A):557-61. PubMed ID: 10226598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of a transferable farnesyl pyrophosphate analogue to Ras by protein farnesyltransferase.
    Chehade KA; Andres DA; Morimoto H; Spielmann HP
    J Org Chem; 2000 May; 65(10):3027-33. PubMed ID: 10814193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.